Mutation News and Research

RSS

Acquisition of a natural mutation primes SARS-CoV-2 for neutralization by a cross-reactive antibody

A team of scientists from the United States reveals that the acquisition of a natural mutation makes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptible to neutralization by a cross-reactive SARS-CoV antibody. The study is currently available on the bioRxiv* preprint server.

22 Sep 2020

Confirmed early re-infection with SARS-CoV-2

As scientists strive to develop commercially viable and effective antivirals and vaccines to counter the growing COVID-19 pandemic, there is considerable uncertainty about how long and how durable the immunity induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is. A new paper recently published in the journal Clinical Infectious Disease in September 2020 reports a confirmed case of re-infection with this virus following recovery.

22 Sep 2020

Researchers examine the impact of human movement on disease spread

Due to continual improvements in transportation technology, people travel more extensively than ever before. Although this strengthened connection between faraway countries comes with many benefits, it also poses a serious threat to disease control and prevention.

22 Sep 2020

Study reveals how people with retinal degenerative disease can maintain night vision

New insight on how people with retinal degenerative disease can maintain their night vision for a relatively long period of time has been published today in the open-access eLife journal.

22 Sep 2020

Discovering a molecule that could interfere with SARS-CoV-2 replication

In this interview, News-Medical speaks to Stepan Nersisyan about his discovery of a molecule that could replicate SARS-CoV-2.

22 Sep 2020

A cost-effective scalable production of SARS-CoV-2 RBD in yeast

A new study by the Argentinian AntiCovid Consortium and published in the preprint server bioRxiv* in September 2020 reports on the successful characterization of the conformation and stability of the SARS-CoV-2 spike protein receptor-binding domain (RBD) in two different cell systems. This may help to accelerate the development of vaccines and neutralizing antibodies.

21 Sep 2020

Soluble ACE2 microbody blocks SARS-CoV-2 entry into lung cells

A new study by researchers at NYU Langone Medical Center and Weill Cornell Medical College and published on the preprint server bioRxiv* in September 2020 reports the potential of an angiotensin-converting enzyme 2 (ACE2)-antibody Fc complex in a new format that seems to offer more significant inhibition of SARS-CoV-2.

21 Sep 2020

In vitro testing suggests effective novel drug combinations for SARS-CoV-2

A recent study published on the preprint server bioRxiv* in September 2020 shows the value of drug combinations to enhance the therapeutic and preventive efficacy of such repositioned drugs in standard antiviral therapy.

20 Sep 2020

New insights into human genetics

Who are we? Where did we come from? How did we get here? Throughout the ages, humans have sought answers to these questions, pursuing wisdom through religion, philosophy, and eventually science.

19 Sep 2020

Genetic variants of human ACE2 are differentially recognized by SARS-CoV-2

Scientists at the University of Wisconsin reveals that the genetic variants of human angiotensin 2 (ACE2) receptors can have altered recognition by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. The study is currently available on the bioRxiv* preprint server.

18 Sep 2020

S-pseudotyped VLPs offer promising COVID-19 vaccine platform

A new study published on the preprint server bioRxiv* in September 2020 reports on a Moloney murine leukemia virus (MLV) platform that produces VLPs expressing the important spike antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Sep 2020

Engineered, high-affinity ACE2 receptors neutralize SARS-CoV-2

In a study published in the preprint server bioRxiv, researchers from the Kyoto Prefectural University of Medicine and Osaka University Japan, discuss how they engineered ACE2 to enhance its affinity to RBD in human cells.

17 Sep 2020

Optimal antibody combinations and Fc binding inhibit SARS-CoV-2 in vivo

A recent study by researchers at the University of North Carolina at Chapel Hill and The Rockefeller University and published on the preprint server bioRxiv in September 2020 shows that a combination of neutralizing antibodies with intact Fc effector function can effectively reduce the viral load and prevent infection.

17 Sep 2020

SARS-CoV-2 with D614G mutation is prevalent in central India

A team of scientists at the Defence Research and Development Establishment, India, reveals that there are multiple viral introduction events in central India, and SARS-CoV-2 with D614G mutation is the prevalently circulating strain.

16 Sep 2020

Study highlights role of specific protein in the mass production of antibodies

Antibodies play a fundamental role in medicine, and antibody-mediated immune response is the ultimate target in the quest for a vaccine to defeat the current pandemic.

16 Sep 2020

SARS-CoV-2 infection severity linked to superior humoral immunity against the S-protein

In a recent bioRxiv* preprint paper, Jenna J. Guthmiller et al., focus on the acute infection of SARS-CoV-2 and observe that the humoral immunity is distinctive with the infection stage and viral antigens.

16 Sep 2020

Scientists unravel the molecular mechanism underlying the causes of colorectal cancer

A team of scientists has unraveled the molecular mechanism behind one of the causes of colorectal cancer, and a treatment target.

15 Sep 2020

3D printed nanoparticle biosensing platform detects SARS-CoV-2 antibodies within seconds

Pandemics caused by novel infectious agents like the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Zika, or Ebola virus seriously impact human health and lives while also overwhelming health care systems all over the world. Early detection and diagnosis allow isolation of the infected patients and contact tracing, which can mitigate the spread of the virus and save lives, especially when a significant number of the patients are asymptomatic.

14 Sep 2020

Researchers identify microRNA molecules that could repress the replication of human coronaviruses

HSE University researchers have found microRNA molecules that are potentially capable of repressing the replication of human coronaviruses, including SARS-CoV-2.

14 Sep 2020

A map of SARS-CoV-2 escape mutations enables the development of therapeutic antibody cocktails

A recent tour-de-force study by the US researchers describes a comprehensive approach to completely map mutations to the SARS-CoV-2 receptor-binding domain (RBD) that escape antibody binding – enabling, in turn, rational design of antibody therapeutics and appraisal of the antigenic consequences of viral evolution. The results are currently available in a bioRxiv preprint paper.

13 Sep 2020